DiaSorin SpA, a leading biotechnology company, represents a set of core values and corporate philosophy that defines its operations. The company is driven by a commitment to innovation, aiming to develop and provide cutting-edge diagnostic solutions. DiaSorin SpA prioritizes quality, ensuring precise and reliable results in healthcare diagnostics to improve patient outcomes. With a strong emphasis on research and development, the company tirelessly works towards advancements in the field of diagnostics for a variety of diseases. DiaSorin SpA combines scientific expertise and technological advancements to deliver high-performance products that meet the evolving needs of the healthcare industry.

DiaSorin SpA is primarily present in various countries and regions across the globe. Some of the main areas where the company operates include Italy, the United States, Europe, Asia Pacific, Latin America, and the Middle East. With its strong presence in multiple markets, DiaSorin SpA is able to cater to the healthcare and diagnostics needs of a wide range of customers worldwide.

DiaSorin SpA has achieved several significant milestones in its corporate journey. The renowned Italian biotechnology company has excelled in multiple areas since its inception. DiaSorin has made notable progress in molecular diagnostics, infectious diseases, and hormonal testing. Over the years, the company has expanded its product portfolio, extended its global presence, and strengthened strategic partnerships. DiaSorin's innovative technologies and cutting-edge solutions have revolutionized the medical diagnostic industry. With a commitment to continuous innovation and exceptional customer service, DiaSorin SpA has established itself as a leading player in the international healthcare sector.

DiaSorin SpA is a leading global biotechnology company, specializing in the development and production of innovative diagnostic solutions. Founded in 1968 and headquartered in Italy, DiaSorin has grown to become a trusted name in the field of in vitro diagnostics. The company offers a wide range of high-quality products and services for clinical diagnostics, including immunoassays, molecular diagnostics, and automation systems. With a strong focus on research and development, DiaSorin continues to drive innovation in the healthcare industry. Today, it operates in more than 90 countries worldwide, serving healthcare professionals and patients with reliable and accurate diagnostic solutions.

The main competitors of DiaSorin SpA in the market are Roche Diagnostics, Abbott Laboratories, and Siemens Healthineers.

DiaSorin SpA is primarily active in the healthcare and diagnostics industry. As a leading company in this field, DiaSorin focuses on developing and manufacturing innovative solutions for clinical diagnostics and infectious diseases. With its extensive range of assays and instruments, DiaSorin serves various sectors including hospitals, laboratories, and research facilities. By combining technology and expertise, DiaSorin delivers reliable and accurate diagnostic solutions to support healthcare professionals in making informed medical decisions.

DiaSorin SpA operates as a global leader in the field of biotechnologies. The company focuses on developing and manufacturing healthcare diagnostics solutions. DiaSorin's business model revolves around providing a wide range of innovative diagnostic tests to help physicians and laboratories in the accurate and timely diagnosis of diseases. By leveraging its advanced technology platforms, DiaSorin aims to improve patient care and outcomes by enabling early disease detection, monitoring treatment efficacy, and identifying potential risks. With a commitment to research and development, DiaSorin continually expands its product portfolio to address emerging healthcare needs and deliver reliable diagnostic solutions worldwide.

مُعامل القيمة السوقية إلى الأرباح لـ DiaSorin SpA هو ٢٩٫١١.

مُعامِل القيمة إلى المبيعات DiaSorin SpA هو ٤٫٦٤.

نقاط جودة AlleAktien لـ DiaSorin SpA هي 6/10.

المتوقعة DiaSorin SpA الإيرادات هي ١٫٢٠ مليارات EUR.

صافي الربح المتوقعة DiaSorin SpA هو ١٩٠٫٧٩ مليون. EUR.

DiaSorin SpA is an internationally active company in the medical and diagnostics industry, providing customized solutions for analysis procedures and diagnostic tests. It is headquartered in Italy and has branches in Europe, North America, Asia, and Africa. DiaSorin is a leading provider of medical diagnostic tests worldwide, and it operates in three main business areas: diagnostics, infectious diseases, and lifestyle. The diagnostics segment includes products for the chemical analysis of blood, urine, and stool, as well as test kits for screening human hormones, vitamins, and tumor markers. The company also offers automated solutions for immunological tests. The infectious diseases segment specializes in tests for diseases such as HIV, Hepatitis B and C, and tuberculosis. DiaSorin provides tests for the diagnosis of infections caused by bacteria, viruses, and fungi. The lifestyle segment includes diagnostic tests for monitoring endocrine, metabolic, and autoimmune diseases, as well as tests for measuring Vitamin D levels. DiaSorin has established itself as a leader in the field of medical diagnostics and life sciences, developing innovative solutions to support healthcare professionals in diagnosis, treatment planning, and therapy monitoring. It has strong partnerships with clinical laboratories worldwide and collaborates closely with universities and research institutions to drive medical innovations and develop new tests. DiaSorin has also emerged as a leader in the development of diagnostic tests for COVID-19 and offers customized solutions to combat the pandemic. Overall, DiaSorin is a leading provider of diagnostic tests globally, offering a wide range of customized solutions and fostering innovation in medical diagnostics.

يوزع DiaSorin SpA أرباحًا قدرها ١٫٠٥ EUR من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ DiaSorin SpA في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـDiaSorin SpA هو IT0003492391.

رمز WKN لـ DiaSorin SpA هو A0MTB2.

الرمز المُختصر لـ DiaSorin SpA هو DIA.MI.

خلال آخر 12 شهراً، دفعت DiaSorin SpA توزيعات أرباح بقيمة ١٫١٠ EUR . وهذا يعادل عائد توزيعات أرباح يقارب ١٫١٠ %. ومن المتوقع أن تدفع DiaSorin SpA خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ١٫٢٤ EUR.

نسبة توزيعات الأرباح الحالية لـ DiaSorin SpA هي ١٫١٠ %.

DiaSorin SpA يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر يونيو, يونيو, يونيو, يونيو.

DiaSorin SpA دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة ١٫٢٤ EUR. وهذا يعادل عائد توزيعات أرباح قدره ١٫٢٤ %.

DiaSorin SpA يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة ١٫١٥ EUR من DiaSorin SpA المُعلن عنها في ٢٢‏/٥‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٢٠‏/٥‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ٢٢‏/٥‏/٢٠٢٤.

في العام 2023، وزعت DiaSorin SpA ١٫٠٥ EUR كأرباح أسهم.

يتم توزيع أرباح DiaSorin SpA بالعملة EUR.